Moreover, the results of subgroup analysis showed that SJZD could increase the CD3+, CD4+, and CD4+/CD8+ of patients with esophageal or gastric cancer, and decrease the CD8+ of esophageal cancer. The gene discussed is CD8A; the disease is gastric cancer.